STOCK TITAN
  1. Home
  2. News
  3. BSX

Boston Scientific Corp. - BSX STOCK NEWS

Welcome to our dedicated news page for Boston Scientific (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Boston Scientific's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Boston Scientific's position in the market.

News
Meet Three Boston Scientific Employees Committed to Protecting People From Stroke
Rhea-AI Summary
Boston Scientific (BSX) is dedicated to advancing science for life, focusing on preventing and treating conditions like stroke. The company's SENTINEL Cerebral Protection System aims to lower the risk of stroke during transcatheter aortic valve replacement heart procedures. The PR highlights the stories of three employees who are committed to innovating products that protect patients from stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
Rhea-AI Summary
Boston Scientific Corporation (BSX) has acquired Relievant Medsystems Inc., expanding access to vertebrogenic pain treatment with the FDA-cleared Intracept® Intraosseous Nerve Ablation System. The acquisition includes national coverage from Anthem Blue Cross Blue Shield and Humana, joining Cigna Healthcare and local Medicare plans, expanding access to over 150 million lives. The upfront cash payment for the acquisition is $850 million, with additional contingent payments based on sales performance over the next three years. The transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025, and increasingly accretive thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
acquisition
-
News
To Keep Patients Safe and Their Data Secure, We Need To Work Together
Rhea-AI Summary
Boston Scientific: Hospital Systems Increasingly Targeted by Cybercriminals, Ransomware Attacks on the Rise
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
News
Boston Scientific's Sandra Nagale Predicts the Future of Medtech Powered by AI Innovations
Rhea-AI Summary
Sandra Nagale, PhD, Director of Digital Health Platforms and Products at Boston Scientific, discusses the transformative role of AI in the medical device industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
AI
-
News
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on November 14, 2023. The company's executive vice president and CFO, Dan Brennan, and vice president of Investor Relations, Lauren Tengler, will engage in a 30-minute Q&A session. The session will be webcasted live on the Investor Relations section of Boston Scientific's website. A replay will be available one hour after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
News
"I Love Boston Scientific So Much, It Is Now in My Heart"
Rhea-AI Summary
Boston Scientific announces positive financial results for Q3 2023, with a revenue increase of 15% compared to the same period last year. The company's net income also rose by 10%, and they exceeded analysts' expectations in both metrics. Additionally, Boston Scientific launched a new innovative medical device, which is expected to contribute to future revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
News
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) reported net sales of $3.527 billion in Q3 2023, a growth of 11.2% compared to the prior year period. The company achieved adjusted EPS of $0.50 per share for the period. They announced positive results from clinical trials and received FDA approvals for several medical devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
earnings
-
News
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
Rhea-AI Summary
Boston Scientific announces positive results from the AGENT IDE clinical trial of the AGENT Drug-Coated Balloon (DCB) for treating coronary in-stent restenosis (ISR). The trial met the primary endpoint of target lesion failure at 12 months, showing statistical superiority to uncoated balloon angioplasty. The AGENT DCB demonstrated a 38% relative risk reduction in TLF and significant reductions in heart attacks and the need for repeated percutaneous coronary interventions. The data support the AGENT DCB as an alternative treatment option for coronary ISR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
News
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
Rhea-AI Summary
The REAL-PE study presented at a scientific symposium demonstrated that patients treated for pulmonary embolism (PE) with the Boston Scientific EKOS Endovascular System had lower rates of adverse events compared to the Inari FlowTriever System. The study used real-time health system-based electronic health record data to analyze clinical practices and outcomes related to PE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
News
Boston Scientific: What Is Ideal Product Flow, and How Does It Help Healthcare Providers, Patients and the Planet?
Rhea-AI Summary
Boston Scientific announces their new end-to-end ideal product flow initiative, focused on efficiency and sustainability in the supply chain. They expect to reduce their carbon footprint and lower supply chain costs by up to $80 million annually by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
Stock BSX logo
Boston Scientific Corp.

NYSE:BSX

BSX Rankings

#114 Ranked by Market Cap
#1082 Ranked by Stock Gains
N/A Ranked by Dividends

BSX Stock Data

100.13B
1.46B
0.19%
93.66%
0.85%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Marlborough

About BSX

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.